Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Markus Dietlein

Showing results (141-150 of 141) with videos related to

Pageof 15
Sort By:
You have reached the last page of results.This site can display upto 141 results.
Lancet (London, England)|July 6, 2024
Assessing the efficacy and tolerability of PET-guided BrECADD versus eBEACOPP in advanced-stage, classical Hodgkin lymphoma (HD21): a randomised, multicentre, parallel, open-label, phase 3 trialPeter Borchmann, Justin Ferdinandus, Gundolf Schneider, et al.
Pageof 15

Showing results (141-150 of 141) with videos related to

Sort By:
Pageof 15
You have reached the last page of results.This site can display upto 141 results.
Lancet (London, England)|July 6, 2024
Assessing the efficacy and tolerability of PET-guided BrECADD versus eBEACOPP in advanced-stage, classical Hodgkin lymphoma (HD21): a randomised, multicentre, parallel, open-label, phase 3 trialPeter Borchmann, Justin Ferdinandus, Gundolf Schneider, et al.
Pageof 15